Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies:

Anna Rada1, Anne Hagemann1, Charlotte Aaberg Poulsen1

  • 1From the Department of Epileptology (Krankenhaus Mara) (A.R., C.G.B., U.S.), Medical School, Bielefeld University, Campus Bielefeld-Bethel; Society for Epilepsy Research (A.H.), Bielefeld, Germany; Department of Neurology (C.A.P., M.B.), Odense University Hospital; Department of Clinical Research (M.B.), University of Southern Denmark, Odense, Denmark; Department of Epileptology (T. Baumgartner, R.S.), University Hospital Bonn, Germany; Department of Immunology and Biotechnology (T. Berki), University of Pécs, Medical School, Hungary; Department of Neurology (J.B., Y.C., M.J.T., J.M.V.), Erasmus Medical Center, Rotterdam, Zuid-Holland, the Netherlands; Division of Epilepsy (J.W.B., K.M.S.), Department of Neurology, Mayo Clinic, Rochester, MN; NYU Comprehensive Epilepsy Center (A.C., C. Steriade), New York; French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (N.L.C.-P., A.F., J. Honnorat, S.M.-C.), Hospices Civils de Lyon, Hôpital Neurologique, UMR MELIS Inserm 1314 / CNRS 5284, Université Claude Bernard Lyon1, France; Department of Neurology (M.E., P.M.), Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic; Department of Neurology (A.R.F., J. Hébert), Columbia University Irving Medical Center (CUIMC)/New York Presbyterian Hospital, New York; Department of Neurology (Z. Hayden), Medical School, University of Pécs, Pécs, Hungary; Division of Neurology (J. Hébert), University of Toronto, Ontario, Canada; Epilepsy-Center Berlin-Brandenburg (M.H., M.I.-F.), Department of Neurology, Charité - Universitätsmedizin Berlin, Germany; Department of Neurology (Z. Hong), West China Hospital, Sichuan University, Chengdu, China; Oxford Autoimmune Neurology Group (S.R.I., S.R., C.E.U.), Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom; Department of Neurology and Neurosciences (S.R.I.), Mayo Clinic, Jacksonville, FL; Department of Neurology with Institute of Translational Neurology (S.K., C. Strippel), University Hospital Münster, Germany; Translational Neuroimmunology Group (S.R.), Kids Neuroscience Centre, Children's Hospital at Westmead; Faculty of Medicine and Health, University of Sydney; Department of Neurology, Concord Hospital, Sydney, Australia; Division of Neurology (C.E.U.), Department of Medicine, University of British Columbia, Vancouver, Canada; and Laboratory Krone (C.G.B.), Bad Salzuflen, Germany.

Abstract

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
320
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
385